Stocks Health care RADX

NASDAQ · Health care

Radiopharm Theranostics Ltd (RADX)

Radiopharm Theranostics Ltd reported revenue of $3.6M in fiscal 2025, up 1,114.3% from a year earlier. It posted a net loss of $38.3M. At June 30, 2025 it held $29.1M in cash.

Watch RADX in 60 seconds

What Radiopharm Theranostics Ltd does

Radiopharm Theranostics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RADX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Where RADX ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Radiopharm Theranostics Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 23, 2026
   Securities offering prospectus 424B3
2. September 22, 2026
   Foreign issuer update 6-K
3. September 14, 2026
   Foreign issuer update 6-K
4. September 14, 2026
   Form F-3 filing F-3
5. September 11, 2026
   Foreign issuer update 6-K
6. September 9, 2026
   Foreign issuer update 6-K
7. August 28, 2026
   Foreign issuer update 6-K
8. August 27, 2026
   Foreign issuer update 6-K
9. August 26, 2026
   Foreign issuer update 6-K
10. August 20, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 8, the latest on May 6, 2026. Insider transactions on SEC

Who owns RADX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RADX

What does Radiopharm Theranostics Ltd do?

Radiopharm Theranostics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RADX.

Is Radiopharm Theranostics Ltd profitable?

No. In fiscal 2025 it reported a net loss of $38.3M on revenue of $3.6M.

How much revenue does Radiopharm Theranostics Ltd make?

In fiscal 2025 Radiopharm Theranostics Ltd reported revenue of $3.6M. That is 1,114.3% more than a year earlier.

When did Radiopharm Theranostics Ltd last report?

Its newest filing of any kind is the securities offering prospectus from September 23, 2026.

Similar companies

Compare RADX with

Compare RADX with any company

Follow RADX

Get an email when Radiopharm Theranostics Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow RADX: get an email when it files

Where the numbers come from

Financial figures are the values Radiopharm Theranostics Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.